Farlong Holding, which sells dietary supplements and herbal products rooted in traditional Chinese medicine, filed on Friday with the SEC to raise up to $23 million in an initial public offering.
Based in the US, Farlong operates through subsidiary Longstar Healthpro, doing business as Farlong Pharmaceutical and Farlong Nutraceutical. The company develops product formulations and engages contract manufacturers, a significant portion of which are located in China, to produce proprietary supplements, which it then markets and distributes. Its herbal extract powders and dietary supplements are marketed as aiming to improve digestive health, brain health, blood pressure, heart health, joint health, and women’s overall health, containing ingredients like Notoginseng extract, White Button Mushroom, and Breviscapine.
The Walnut, CA-based company’s subsidiary was founded in 1999, and it booked $839 thousand in revenue for the 12 months ended June 30, 2025. It plans to list on the Nasdaq under the symbol AFA. US Tiger Securities is the sole bookrunner on the deal. No pricing terms were disclosed.
